Sanfilippo Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Novel HGSNAT Variants Identified in the Oldest Siblings With MPS IIIC: Functional Characterization and Literature Review.
Yu Owen et al. — American journal of medical genetics. Part A (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41883052/
- 2.
Pathogenic Variants in HGSNAT associated with Autosomal Recessive Retinitis Pigmentosa without Overt Sanfilippo Syndrome.
Haefeli Lorena M et al. — Retinal cases & brief reports (6 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42351339/
- 3.
Cerebrospinal fluid heparan sulfate as a biomarker for neuronopathic mucopolysaccharidoses: Rationale and regulatory challenges.
Muenzer Joseph et al. — Molecular genetics and metabolism (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41935419/
- 4.
Mapping Sanfilippo Syndrome: A Multisystem Clinicopathological Autopsy.
Trandafirescu Mioara-Florentina et al. — Diagnostics (Basel, Switzerland) (18 May 2026)
https://pubmed.ncbi.nlm.nih.gov/42196893/
- 5.
Molecular Modeling of N-Acetylglucosamine Binding to the I154R Mutant of NAGLU: Pathogenic Insights into Sanfilippo Syndrome Type B.
Kannan Priyanka et al. — International journal of molecular sciences (15 May 2026)
https://pubmed.ncbi.nlm.nih.gov/42196382/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Recruiting — Phase 2 — Ultragenyx Pharmaceutical Inc
https://clinicaltrials.gov/study/NCT02716246
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sanfilippo Syndrome
Sanfilippo syndrome (MPS III) is a rare lysosomal storage disorder caused by enzyme deficiencies that result in heparan sulfate accumulation in cells. It causes progressive neurodegeneration, intellectual regression, and behaviour problems in childhood. Australian families have been pivotal in advocating for gene therapy research.
Most Recent Research
Mucopolysaccharidosis type IIIC (MPS IIIC) is a rare lysosomal storage disorder caused by biallelic pathogenic variants in the HGSNAT gene, encoding heparan-α-glucosaminide N-acetyltransferase. Deficient enzymatic activity leads to heparan sulfate accumulation, resulting in progressive central nervous system involvement and multisystem disease. Clinical features typically include developmental delay, intellectual disability, behavioral disturbances, coarse facial features, hypertrichosis, and hearing loss. This report describes the oldest documented siblings with MPS IIIC: a male diagnosed at 46 years (currently 50 years) and his sister diagnosed at 38 years (currently 42 years). Both presented with bilateral sensorineural hearing loss, retinitis pigmentosa, intellectual disability, mildly coarse facial features, and hypertrichosis. Molecular analysis identified two novel HGSNAT variants: c.1205T>C; p.(Leu402Pro) and c.1565C>A; p.(Thr522Lys). Functional studies demonstrated markedly reduced heparan-α-glucosaminide N-acetyltransferase activity and elevated urinary heparan sulfate excretion, providing biochemical evidence supporting variant pathogenicity and confirming the diagnosis. These cases expand both the phenotypic and genotypic spectrum of MPS IIIC and underscore the importance of considering this disorder in adults with multisystem involvement. Functional characterization proved essential for establishing a definitive diagnosis when molecular findings alone were inconclusive.
Common Questions
What is Sanfilippo Syndrome?
Sanfilippo syndrome (MPS III) is a rare lysosomal storage disorder caused by enzyme deficiencies that result in heparan sulfate accumulation in cells. It causes progressive neurodegeneration, intellectual regression, and behaviour problems in childhood. Australian families have been pivotal in advocating for gene therapy research.
How many clinical trials are available for Sanfilippo Syndrome?
RareWays currently indexes 37 clinical trials for Sanfilippo Syndrome, of which 8 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Sanfilippo Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Sanfilippo Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.